Karin N. Weldingh
Malov, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform.
Journal: Frontiers in immunology
Published: February 21, 2025
Factor VIII Activity and Factor VIII Inhibitors Can Be Measured Accurately in Plasma Containing Mim8 by Using Specific Chromogenic Assays.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: September 26, 2024
CTLA4-Ig prevents development of neutralizing antibody formation after continuous treatment with human FVIII in HA rats.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: January 18, 2022
A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys.
Journal: Journal of thrombosis and haemostasis : JTH
Published: June 29, 2021
Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A.
Journal: Journal of thrombosis and haemostasis : JTH
Published: September 23, 2015
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.
Journal: Journal of thrombosis and haemostasis : JTH
Published: May 11, 2015
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.
Journal: Journal of thrombosis and haemostasis : JTH
Published: March 18, 2014
Proteomic profiling of Mycobacterium tuberculosis identifies nutrient-starvation-responsive toxin-antitoxin systems.
Journal: Molecular & cellular proteomics : MCP
Published: January 25, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026